We're excited to announce our brand new initiative in molecular diagnostics: the Molecular Automation Network. This network is a consortium of companies that are currently active in molecular diagnostics & automation. Its purpose is to connect the MDx industry better, enabling more complete solutions and end to end workflows across the globe.

Our first partner

In our mission to enable better and more efficient diagnostics, we're excited to welcome Hamilton Robotics as one of the first partners into the network. Hamilton Robotics is a key player in the liquid handling and robotics market. Read the full press release below.

Hamilton & UgenTec partnership

Press release:

UgenTec today announced the founding of a new network dubbed the Molecular Automation Network, along with a new partner in the form of Hamilton Robotics.

The network aims to facilitate business and technical information exchange between automated liquid handling workstations manufacturers, real-time PCR device manufacturers, software and Dx companies. Its goal is to provide laboratories with more encompassing solutions to their automation problems by creating collaborations between industry leaders.

In the network, Hamilton Robotics and UgenTec will collaborate on new business opportunities, exchange of technical expertise and integration of existing software and hardware systems.

“UgenTec is well on its way to becoming the golden standard of qPCR workflow software with their platform FastFinder,” said Guido Meneghini, International Sales Director at Hamilton Robotics, “their software expertise & existing partnerships with MDx companies will enable us to consolidate our position in MDx. We are excited to be the first company to join the Molecular Automation Network and look forward to building more durable partnerships.”

“Hamilton’s automated technologies have a proven track record of success, it’s great to have a company such as theirs vouch for our new initiative,” said Steven Verhoeven, chief executive officer at UgenTec. “Diagnostic companies are experiencing significant hurdles in adding PCR assays to existing and regulated PCR platforms, and even more in fully automating the end-customers’ laboratory workflow. Therefore, we see a considerable interest with assay, hardware, and device providers to join the network. With our partners, we will be able to provide molecular laboratories with a flexible and extensible end to end automation solutions for qPCR testing.”